A Rutgers-led plan urges long-term, co-ordinated studies to test whether disruptions to the microbiome in pregnancy and early childhood help drive conditions including obesity, asthma and food allergies.
Researchers are pushing for a large-scale, co-ordinated push to understand how the human microbiome influences chronic disease, arguing that the field now needs the kind of ambition and funding that turned other areas of medicine from speculation into practice. Rutgers scientists Martin Blaser and Maria Gloria Dominguez-Bello are among the authors of a plan published in Nature Medicine that sets out 10 priorities for studying whether microbial disruption helps drive conditions such as obesity, asthma and food allergies, and whether the microbiome can be restored to support better health.
The microbiome is the vast community of bacteria, fungi, viruses and other microbes that live on and inside the body. The National Institute of Environmental Health Sciences says these organisms play a central role in digestion, immunity and protection against pathogens. That has made them a growing focus for scientists looking for links between early-life exposures and later disease, particularly because antibiotics, caesarean births, infant formula and highly processed diets can all alter microbial communities.
The Rutgers-led proposal places particular emphasis on pregnancy and the first 1,000 days of life, from conception through a child’s second birthday. Dominguez-Bello said that period offers a valuable window for testing whether protecting the microbiome’s early development could improve health years later. The authors want long-term human studies that follow people from pregnancy into adolescence, to determine whether changes caused by antibiotics or caesarean delivery actually contribute to later metabolic or allergic disease, rather than simply appearing alongside it.
Their wider agenda also reflects a practical problem in the field: much of the existing evidence comes from small studies in wealthy countries, which makes it harder to compare results and apply them more broadly. The researchers are calling for standardised methods, stronger public education and closer links between microbiome science, nutrition guidance and medical training. Blaser said he hopes to see detailed proposals for specific studies and education programmes in the next fiscal year.
The appeal comes as the field is already producing a few concrete clinical gains. The US Food and Drug Administration has approved Rebyota and Vowst, two microbiome-based products designed to help prevent recurrent Clostridioides difficile infection in adults after antibiotic treatment. The CDC has also pointed to the value of microbiome science in infection prevention and public health, while scientists continue to explore its possible role in cancer immunotherapy, Parkinson’s disease and Alzheimer’s disease.
The proposal also appears to fit with a broader policy shift in Washington. According to the article in News Medical, Health Secretary Robert F Kennedy Jr called for microbiome research to become a national “moonshot” priority at a symposium in May, and the new framework offers a rough outline of what that would require. But the authors stress that the next step is not a blank cheque: it is the funding of specific, testable projects that can be carried out safely and at scale.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
